Whole-exome sequencing reveals a rapid change in the frequency of rare functional variants in a founding population of humans

PLoS Genet. 2013;9(9):e1003815. doi: 10.1371/journal.pgen.1003815. Epub 2013 Sep 26.

Abstract

Whole-exome or gene targeted resequencing in hundreds to thousands of individuals has shown that the majority of genetic variants are at low frequency in human populations. Rare variants are enriched for functional mutations and are expected to explain an important fraction of the genetic etiology of human disease, therefore having a potential medical interest. In this work, we analyze the whole-exome sequences of French-Canadian individuals, a founder population with a unique demographic history that includes an original population bottleneck less than 20 generations ago, followed by a demographic explosion, and the whole exomes of French individuals sampled from France. We show that in less than 20 generations of genetic isolation from the French population, the genetic pool of French-Canadians shows reduced levels of diversity, higher homozygosity, and an excess of rare variants with low variant sharing with Europeans. Furthermore, the French-Canadian population contains a larger proportion of putatively damaging functional variants, which could partially explain the increased incidence of genetic disease in the province. Our results highlight the impact of population demography on genetic fitness and the contribution of rare variants to the human genetic variation landscape, emphasizing the need for deep cataloguing of genetic variants by resequencing worldwide human populations in order to truly assess disease risk.

Publication types

  • Research Support, Non-U.S. Gov't

MeSH terms

  • Canada
  • Demography
  • Disease Susceptibility*
  • Exome / genetics*
  • France
  • Gene Frequency
  • Genetics, Population
  • Humans
  • Mutation*
  • Polymorphism, Single Nucleotide
  • Sequence Analysis, DNA / methods*
  • White People / genetics

Grants and funding

This study was supported by Canadian Foundation for Innovation, FRSQ and Genome Quebec grants to PA, and by research funds provided by the Terry Fox Foundation and the Canadian Institutes for Health Research. EH is a scholar of the Fonds de la Recherche en Santé du Québec. AH is supported by a Fonds de la Recherche en Santé du Québec (FRSQ) fellowship. JFS is the recipient of a Cole Foundation scholarship. DS holds the François-Karl-Viau Research Chair in Pediatric Oncogenomics. The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.